Galderma Announces Record 2023 Net Sales of Over 4 B USD and Significant Core EBITDA Margin Expansion

Galderma, a leading global dermatology company, has announced its record 2023 net sales of over 4 billion USD and significant core EBITDA margin expansion. The company delivered against full year guidance for another consecutive year with strong financial performance.

In FY 2023, Galderma achieved net sales of 4.082 billion USD, up 8.5% year-on-year on a constant currency basis. This represents a significant increase from the previous year and surpassed the company's guidance range of 6-9% net sales growth for FY 2023.

The strong financial performance of Galderma was driven by its core business, which includes dermatology products such as Dysport, Orbiron, and EltaMD UV Clear. The company's focus on innovation and product development has helped it to maintain a leading position in the global dermatology market.

In addition to strong net sales growth, Galderma also achieved significant core EBITDA margin expansion in FY 2023. This was driven by the company's ability to optimize its cost structure and improve operational efficiency.

Overall, Galderma's record 2023 net sales and significant core EBITDA margin expansion are a testament to the company's strong financial performance and leadership position in the global dermatology market.